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ORIGINAL ARTICLE
Purpose: The cervical lymph nodes are the most common sites of locoregional 
recurrence in patients with papillary thyroid carcinoma (PTC). Accurate tumor 
localization is important for the successful removal of impalpable recurrences in the 
cervical lymph nodes. We evaluated the benefits of ultrasound-guided localization 
(UGL) performed by a single surgeon on site.
Methods: Of 53 PTC patients who underwent reoperation for impalpable nodal 
recurrences, 32 (group 1) were assessed only using preoperative imaging, while 21 
(group 2) were additionally evaluated by on-site UGL performed by the operating 
surgeon. Postoperative outcomes were compared between the two groups.
Results: Operation times were significantly shorter (P < 0.001) and the mean size of 
the resected lymph nodes were smaller (P = 0.013) for group 2 patients. More lymph 
nodes were identified and resected in group 1 (3.56 vs. 3.19), but the rate of positive 
lymph nodes was significantly higher in group 2 (P < 0.001). There were no 
differences between the two groups in terms of resection success rate, complication 
rate, and postoperative hospital stay. During a mean follow-up period of 27.6 
months, 52 patients (98.1%) showed no evidence of recurrence on routine ultrasound, 
and serum thyroglobulin concentrations remained < 1 ng/mL in 49 patients (92.5%). 
Conclusion: On-site UGL performed by the operating surgeon is useful for accurate 
resection of impalpable nodal recurrences in PTC patients.
Journal of the Korean Surgical Society
JKSS
INTRODUCTION
Although patients with papillary thyroid carcinoma (PTC) have excellent prognosis, 
between 5% and 40% have persistent or recurrent disease even after curative surgery 
[1,2]. Assays of serum thyroglobulin (Tg) concentrations combined with high-
resolution ultrasound are widely used for postoperative follow-up, enabling early 
detection of recurrence and more prompt management [3-8].
Most locoregional recurrences develop in the cervical lymph nodes, and the 
majority can be controlled by surgical removal if there is no extensive invasion or 
distant metastasis [1-3,9-13]. Difficulties may be encountered, however, during re-
exploration of the neck. For example, extensive scarring and fibrosis resulting from 
previous surgery can distort normal anatomic landmarks, prolonging operation 
time and increasing the rate of operative morbidities [13,14]. These problems may 
occur more frequently when the recurrent lesions are impalpable. Thus, accurate 
localization of recurrent lesions may be an important factor for successful outcomes.
Several methods have been described for the localization of impalpable, recurrent 
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lesions, including radioiodine-detected probe-guided surgery 
[15], intraoperative ultrasound [16], preoperative tattooing with 
charcoal [17], hook-needle positioning in the lesion [18], and 
preoperative skin marking under ultrasound guidance [19].
On-site ultrasound-guided localization (UGL) by surgeon 
has recently been introduced at our institution . We therefore 
investigated the benefits of on-site UGL for impalpable nodal 
recurrences in PTC patients.
METHODS
From March 2007 to September 2009, a total of 53 PTC 
patients underwent surgery for the removal of impalpable 
nodal recurrences in the central compartment (level 6) of 
the neck at the Thyroid Cancer Center, Gangnam Severance 
Hospital, Yonsei University College of Medicine. All patients 
had previously undergone a total thyroidectomy and central 
compartment lymph node dissection. Ultrasound follow-up in 
all patients showed no dal recurrences in single focus, which 
was confirmed by fine needle aspiration cytology. Patients 
with lateral neck or mediastinal lymph node recurrences 
were excluded from the study because of the variety of 
surgical approaches and ope rative procedures. All patients 
also underwent a computed tomographic (CT) scan of the 
neck. Chest radiography, CT scans of the chest and abdomen, 
and/or positron emission tomography (PET) were selectively 
performed to assess distant metastases.
The medical records of all patients were retrospectively 
reviewed, and the study protocol was approved by the Insti-
tutional Review Board of the hospital. 
The patients were divided into two groups. Patients in 
group 1 (n = 32) underwent surgery based on the findings 
of the preoperative ultrasound and neck CT scans. Surgeons 
predicted the location of recurrent lymph node by estimating 
the distance from nearby structures (structures like internal 
jugular vein, common carotid artery, sternal notch) that were 
shown in previously performed imaging studies. No marking 
or tattooing procedures were performed for group I patients. 
Patients in group 2 (n = 21) additionally underwent on-
site UGL in the operating room. UGL was performed after 
general anesthesia and positioning for surgery (neck extended 
position). Under ultrasound guidance, about 0.1 mL of 
methylene blue dye was injected into the recurrent lesion. All 
UGLs were performed by a single surgeon using an ALOKA 
diagnostic ultrasound system (Prosound SSD-3500 plus, 
Tokyo, Japan) and a 12-MHz linear transducer (Fig. 1).
All operations were performed by an experienced thyroid 
surgeon who performs more than 800 cases of thyroid surgery 
annually as the main operator. Previous operation sites were 
used for surgical approach and no patient required extension 
of the previous incision.
Surgical success was defined as: 1) pathologic confirmation 
of recurrence in the resected lymph node; 2) disappearance of 
the lesion on postoperative ultrasound, which was performed 
within a month after surgery. The ultrasound of each patient 
was performed by the same radiologist who had performed 
the fine needle aspiration. We compared the resection success 
rate, operation time, mean size of the resected lymph nodes, 
complication rate, and length of postoperative hospital stay 
between the two groups. The time spent for anesthesia was 
not included in operation time. We also compared resection 
efficiency, determined by counting the total numbers of 
resected and positive lymph nodes. 
Preoperative and postoperative serum Tg concentrations 
were also checked. Postoperatively, all patients had routine 
follow-up with neck ultrasound and serum Tg concentration in 
an out-patient clinic for detection of recurrence or persistence 
of PTC. Within two months of the surgery, serum Tg concen-
trations were measured in T4-off (thyroid-stimulating hor-
mone [TSH]-stimulated) states and, after that, routine mea-
surements were performed every 6 to 12 months in a T4-on 
(TSH-suppressed) state. Serum TSH and anti-Tg antibodies 
were measured concurrently. We considered disease-free 
serum Tg concentrations to be less than 2 ng/mL in a T4-off 
Fig. 1. (A) Transverse ultrasound image of a nodal recurrence (arrow) in central neck, (B) a patient undergoing on-site ultrasound-guided localization of recurrent lymph 
nodes after direct injection of methylene blue dye, and (C) a blue-stained lymph node in operative field (arrow). C, common carotid artery; T, trachea.
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state and less than 1 ng/mL in a T4-on state, based on the 
consensus recommendations of Mazzaferri et al. [20].
Statistical analyses between the groups were performed 
using independent t-tests, Mann-Whitney U tests and Fisher 
exact tests, as warranted.
RESULTS
Of the 53 patients, 43 were female (male to female ratio, 
1:4.3), and the mean patient age was 46.9 years (range, 23 
to 69 years). All the patients had a previous history of total 
thyroidectomy and central compartment node dissection. The 
mean number of previous operations was 1.3 (range, 1 to 2) 
and the mean duration from the most recent to the current 
operation was 66.0 months (range, 7 to 158 months).
We found that operation time was significantly shorter in 
patients evaluated by on-site UGL (group 2) than in those who 
were not (group 1) (102.0 minutes vs. 62.4 minutes, P < 0.001). 
The mean size of the resected lymph node was smaller in 
group 2 patients than in group 1 (1.0 cm vs. 0.8 cm, P = 0.013). 
Resection failure (1 patient) and postoperative complications 
(transient hypocalcemia, 1 patient) each occurred in one of 
the 32 patients in group 1. However, there were no significant 
differences between the groups in terms of resection success 
rate, rate of complications, and length of postoperative hospital 
stay (Table 1).  
The mean number of resected lymph nodes was higher 
in group 1 than group 2 (3.56 vs. 3.19). However, the mean 
number of positive nodes was lower in group 1 than in group 
2 (1.63 vs. 2.29), making the rate of positive node occurrence 
significantly higher in group 2 (51.2 vs. 82.7%, P < 0.001) (Table 
2).
As mentioned above, neck ultrasound and serum Tg con-
centration measurement were performed for postoperative 
follow-up. During a mean follow-up of 27.6 months, there was 
only one patient in group 1 who showed sustained, suspicious 
lesions on neck ultrasound (the patient who failed in resection) 
whereas no patients in group 2 showed abnormal findings on 
ultrasound. In terms of serum Tg concentration, 28 patients 
(28/32) in group 1 and 19 patients (19/21) in group 2 showed 
less than 2 ng/mL in a T4-off state. At the last follow-up, 29 
patients in group 1 and 20 patients in group 2 showed less than 
1 ng/mL in a T4-on state (Fig. 2). There were no significant 
differences between the groups in the number of patients with 
Table 1. Postoperative outcomes in groups 1 and 2
Group 1 
(n = 32)
Group 2 
(n = 21) P-value
Operation time (min) 102.0 ± 37.3 62.4 ± 18.1 <0.001
Size of resected lymph node (cm) 1.0 ± 0.4 0.8 ± 0.2 0.013
Resection success ratea), n (%) 31 (96.9) 21 (100) NS
Patients experiencing complicationsb),
 n (%)
1 (3.12) 0 (0) NS
Postoperative hospital stay (day) 3.1 ± 1.5 3.5 ± 1.9 NS
Values are presented as mean ± standard deviation unless otherwise indicated.
NS, not significant.
a)Success of operation was defined as: 1) pathologic confirmation of recurrence in 
the resected lymph node; 2) disappearance of the lesion on postoperative 
ultrasound. b)Transient hypocalcemia.
Table 2. Resection efficiency in groups 1 and 2
Group 1 
(n = 32)
Group 2 
(n = 21) P-value
No. of resected lymph nodes 3.56 ± 3.39 3.19 ± 3.59
No. of positive lymph nodes 1.63 ± 0.91 2.29 ± 2.37
Percent positive lymph nodes (%) 51.20 ± 31.1 82.70 ± 21.30 <0.001
Values are presented as mean ± standard deviation.
Table 3. Follow-upa) results in groups 1 and 2
Group 1 
(n = 32)
Group 2 
(n = 21) P-value
Follow-up ultrasound 
No evidence of recurrences 31 21 NS
Suspicious findings 1 0 NS
Serum Tg concentration 
Postoperative serum Tgb) <2 ng/mL (T4-off) 28 19 NS
Last serum Tg <1 ng/mL (T4-on) 29 20 NS
NS, not significant; Tg, thyroglobulin.
a)Mean follow-up duration is 27.6 ± 11.9 months. b)Measured within 2 months 
after surgery.
Fig. 2. Preoperative (Pre-op) and last follow-up (F/U) serum thyroglobulin (Tg) 
concentration of (A) group 1 (32 patients) and (B) group 2 (21 patients). Both levels 
were measured in T4-on states. There were 3 patients in group 1 and 1 patient in 
group 2 who showed serum Tg concentrations >1 ng/mL in last follow-up.
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tolerable serum Tg concentration in the postoperative period 
(Table 3). None of the patients showed elevated serum levels of 
anti-Tg antibodies.
DISCUSSION
Recurrences of PTC are not uncommon even after cura-
tive surgery. Postoperative follow-up with high-resolution 
ultrasound, combined with measurements of serum Tg con-
centrations, can increase the rates of detection of pre clinical 
recurrences [3-8]. In contrast to locoregional re currence of 
other malignancies, most locoregional recur rences of PTC 
can be controlled by proper surgical resection, with excellent 
patient prognosis [1-3,9].
The optimal management of preclinical nodal recurrences 
of PTC is unclear. The choice between simple observation and 
surgical removal remains a significant dilemma for clinicians 
[10-12]. Decisions should be made specific to individual pa-
tients, with long-term follow-up required to assess the out-
comes of surgical management. Once they become aware of a 
recurrence of malignancy, however, most patients want these 
lesions to be removed as soon as possible.
In this study, all patients had previously undergone a total 
thyroidectomy with central neck compartment dissection. 
To avoid unnecessarily wide dissections and to minimize 
operative morbidities, we usually selectively resect nodal re-
cur rences after on-site UGL. Indeed, although only 21 of 
the patients in this study were evaluated by on-site UGL, 
it proved useful, not only in reducing the length of surgery, 
but in enabling surgeons to perform more focused, accurate 
resections of nodal recurrences - even those smaller in 
size. By minimizing unnecessary dissections, limited, fo-
cused resections of recurrent foci can reduce postoperative 
morbidities [11,12]. Moreover, on-site UGL has several benefits 
compared to other localization methods. First, the operating 
surgeon can directly detect the location of lymph nodes just 
before the operation, resulting in more accurate resection with 
a more focused approach. Second, there is no need to arrange 
or organize preoperative localization procedures. By enabling 
the surgeon to localize lesions, UGL can eliminate the need 
for other, more time-consuming procedures and shorten 
bothersome preoperative localization procedures. Third, this 
technique is easy to perform and does not take much time 
(less than 5 minutes in our experience). Finally, the injected 
methylene blue dye can easily detect recurrent lymph nodes, 
allowing their effective removal while avoiding unnecessary 
dissection. Also, by staining these lesions, surgeons can be 
confident of their successful removal. In our experience, 
accurately injected methylene blue remains in the recurrent 
nodes for a sufficient period of time (more than 30 to 40 
minutes) during surgery.
Methylene blue is widely used material in medical fields. 
When injected intraveneously, it has a half-life of 5.25 hours 
[21]. In surgical fields, methylene blue is used for lymph node 
staining of thyroid, breast cancer via direct or peritumoral 
injection, and used in parathyroidectomy with intravenous 
infusion [22-24]. Methylene blue is also known as an option 
in the treatment of ifosfamide-induced encephalopathy. In 
patients without predisposing risk factors like serotonergic 
psychiatric medications, use of methylene blue for lymph node 
staining is known as relatively safe [25,26].
In this study, there were some patients who showed elevated 
serum Tg concentrations even after successful resection (6 
patients showed >2 ng/mL in T4-off state and 4 patients 
showed >1 ng/mL in T4-on state) and we could not find any 
abnormal/suspicious lesions in routine examinations, including 
neck ultrasound. The trouble was, even after performing 
additional imaging studies including radioactive iodine scans 
and PET-CT scans, no obvious foci suggesting recurrence or 
persistence of PTC were identified in these patients. As a last 
resort, we are conducting more frequent/close follow-up for 
those patients suspected of residual or recurrent disease in the 
subclinical levels. 
In conclusion, on-site UGL technique performed by a sur-
geon is useful and effective for the resection of recurrent 
impalpable lymph nodes in patients with PTC.
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